| Autor: |
Smok-Kalwat J; Department of Clinical Oncology, Holycross Cancer Center, 25-734 Kielce, Poland., Chmielewski G; Department of Radiation Oncology, Holycross Cancer Center, 25-734 Kielce, Poland.; Institute of Medical Sciences, Collegium Medicum, Jan Kochanowski University, 25-516 Kielce, Poland., Stando R; Department of Radiation Oncology, Holycross Cancer Center, 25-734 Kielce, Poland., Sadowski J; Department of Radiation Oncology, Holycross Cancer Center, 25-734 Kielce, Poland., Macek P; Department of Oncology, Institute of Health Sciences, Collegium Medicum, Jan Kochanowski University, 25-516 Kielce, Poland.; Department of Epidemiology and Cancer Control, Holycross Cancer Centre, 25-734 Kielce, Poland., Kowalik A; Department of Molecular Diagnostics, Holycross Cancer Centre, 25-734 Kielce, Poland.; Division of Medical Biology, Institute of Biology, Jan Kochanowski University, 25-406 Kielce, Poland., Nowak-Ozimek E; Department of Molecular Diagnostics, Holycross Cancer Centre, 25-734 Kielce, Poland., Góźdź S; Department of Clinical Oncology, Holycross Cancer Center, 25-734 Kielce, Poland.; Department of Oncology, Institute of Health Sciences, Collegium Medicum, Jan Kochanowski University, 25-516 Kielce, Poland. |
| Abstrakt: |
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA ) is a well-known oncogene with a high prevalence of mutation in breast cancer patients. The effect of the mutation is a deregulation in phosphatidylinositol 3-kinase-related pathways, and, consequently, in unrestricted cell growth and differentiation. With the advent of precision oncology, PIK3CA has emerged as a pivotal treatment target, culminating in the recent approval of alpelisib. Despite years of research on this genetic alteration, certain aspects of its influence on the prognosis of breast cancer remain ambiguous. The purpose of this analysis is to characterize the clinical picture of breast cancer patients with PIK3CA mutation in comparison to the PIK3CA -wild-type group. We examined 103 tumor samples from 100 breast cancer patients using a next-generation sequencing panel. Presence of the mutation was linked to an older age at diagnosis, a lower expression of Ki67 protein, a greater percentage of tumors expressing progesterone receptors, and a notably higher incidence of metastatic disease at presentation. No significant differences were identified in overall and progression-free survival between the two groups. Our findings enhance the understanding of how PIK3CA mutations shape the clinical and prognostic landscape for breast cancer patients. |
